The approval comes as welcome news for AbbVie, which seeks to strengthen its immunology sales as it faces biosimilar competition for its flagship therapy, adalimumab (Humira).
AbbVie has received FDA approval for a novel biologic, risankizumab-rzaa (Skyrizi), an interleukin-23 inhibitor, for the treatment of plaque psoriasis.
The drug, at a dose of 150 mg, is administered by 2 subcutaneous injections every 12 weeks after initiation doses at week 0 and week 4.
Approval of the biologic was based on data from a global phase 3 psoriasis program. In the ultlMMA-1 and ultlMMA-2 pivotal studies, at 16 weeks, 75% of enrolled patients reached criteria for 90% skin clearance on the Psoriasis Area and Severity Index (PASI 90). PASI 100 was reached by 36% and 51% of patients in the 2 trials, respectively.
At 1 year, 82% and 81% of patients in the trials achieved PASI 90, and 56% and 60% reached PASI 100. An integrated analysis of the 2 trials showed that most patients (88% and 80%, respectively) who achieved PASI 90 or PASI 100 at week 16 maintained their response up to 1 year.
“The approval of Skyrizi is an important advance in the treatment of adults with plaque psoriasis who are seeking high levels of durable skin clearance that can be maintained over time,” said Michael Severino, MD, vice chairman and president of AbbVie, in a statement. “Skyrizi builds on AbbVie’s legacy in immunology, expanding our portfolio to help meet the evolving needs in psoriatic disease and reinforcing our continued pursuit of innovations that improve care for people living with immune-mediated conditions.”
The drug was also recently approved in Canada and Japan. AbbVie has also received a positive opinion for the therapy from the European Medicines Agency’s Committee for Medicinal Products for Human Use and anticipates European authorization for the drug shortly. Furthermore, risankizumab could see an expanded label in the future; phase 3 trials of the drug are underway in Crohn disease and psoriatic arthritis.
The approval comes as welcome news for AbbVie, which seeks to strengthen its immunology sales as it faces biosimilar competition for its flagship therapy, adalimumab (Humira). While sales of the brand-name Humira made up 61% of the company’s revenues in 2018, it has faced competition in the European Union from a host of biosimilars that began to reach the market in October 2018.
In earnings results announced today, AbbVie said that the brand-name adalimumab saw its net international revenues drop to $1.231 billion during the first quarter, a decrease of 27.9% on a reported basis, which the company says was a result of biosimilar competition. US Humira revenue grew by 7.1% last quarter to $2.315 billion, as the company still faces no US biosimilar competitors, but worldwide net revenues for Humira dropped by 5.6% on a reported basis.
Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics
May 13th 2025Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.